Pfizer surges on launching 20-valent Pneumococcal Conjugate Vaccine for adults in India
Pfizer is currently trading at Rs. 5134.85, up by 94.05 points or 1.87% from its previous closing of Rs. 5040.80 on the BSE.
The scrip opened at Rs. 5100.00 and has touched a high and low of Rs. 5188.00 and Rs. 5100.00 respectively. So far 601 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6452.85 on 02-Sep-2024 and a 52 week low of Rs. 3742.90 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 5200.00 and Rs. 4921.45 respectively. The current market cap of the company is Rs. 23554.59 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 19.62% and 16.45% respectively.
Pfizer has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults. Pfizer’s vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease.
It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose. Adults over 50 years of age, as well as individuals with comorbidities such as asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic kidney disease, and diabetes, face a higher risk of developing pneumococcal infections, which can result in complications, hospitalization, and even death.
Timely immunization is critical to reducing the risk of severe illness, hospitalization, and mortality caused by pneumococcal disease. Vaccination with PCVs are considered one of the most effective public health tools for reducing the burden of pneumococcal disease. The introduction of PCV20 in India strengthens Pfizer’s longstanding commitment to preventive health and builds on 25 years of leadership in pneumococcal vaccine innovation.
Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
